<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205711</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000685062</org_study_id>
    <secondary_id>WCTU-FOLFERA</secondary_id>
    <secondary_id>EUDRACT-2009-012151-23</secondary_id>
    <secondary_id>ISRCTN-73199181</secondary_id>
    <secondary_id>CRUK-09/023</secondary_id>
    <secondary_id>WCTU-SPON-671-09</secondary_id>
    <secondary_id>EU-21071</secondary_id>
    <secondary_id>ZENECA-WCTU-FOLFERA</secondary_id>
    <nct_id>NCT01205711</nct_id>
  </id_info>
  <brief_title>Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>FOLFERA</acronym>
  <official_title>A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and&#xD;
      leucovorin calcium, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Zibotentan may be effective in treating&#xD;
      metastatic colorectal cancer that has not responded to oxaliplatin. It is not yet known&#xD;
      whether combination chemotherapy is more effective when given with or without zibotentan in&#xD;
      treating metastatic colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving irinotecan hydrochloride together&#xD;
      with fluorouracil and leucovorin calcium to see how well it works when given with or without&#xD;
      zibotentan in treating patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the anti-tumor activity of the combination of irinotecan hydrochloride,&#xD;
           fluorouracil, and leucovorin calcium (FOLFIRI) with zibotentan (FOLFERA) as measured by&#xD;
           progression-free survival (time-to-event) in patients with metastatic colorectal cancer&#xD;
           after failure of oxaliplatin-containing chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the toxicity profile of FOLFERA and of maintenance zibotentan in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine the feasibility of use of this regimen in these patients.&#xD;
&#xD;
        -  To collect tumor and blood samples for future translational work, including&#xD;
           investigating endothelian A receptor (ETAR) expression, k-RAS/b-RAF status and&#xD;
           alterations in relevant pathways such as Akt, MAPK/ERK.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to study site.&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm A: Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium&#xD;
           IV over 2 hours on day 1; fluorouracil IV over 46 hours beginning on day 1; and an oral&#xD;
           placebo tablet once daily on days 1-14. Treatment repeats every 14 days for 12 courses&#xD;
           in the absence of disease progression or unacceptable toxicity. Patients achieving at&#xD;
           least stable disease then receive oral placebo alone once daily in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm B: Patients receive irinotecan hydrochloride IV over 2 hours, leucovorin calcium IV&#xD;
           over 2 hours on day 1; fluorouracil IV over 46 hours beginning on day 1; and oral&#xD;
           zibotentan once daily on days 1-14. Treatment repeats every 14 days for 12 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Patients achieving at least&#xD;
           stable disease then receive oral zibotentan alone once daily in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and tissue samples are collected periodically for pharmacogenetic, translational, and&#xD;
      biomarker correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up at 30 days and then every 12&#xD;
      weeks for up to 1 year.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability (side effects) and feasibility of use (number of participants requiring dose delays or reductions and/or treatment withdrawal)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">111</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zibotentan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer&#xD;
&#xD;
               -  Metastatic disease with no bone metastases&#xD;
&#xD;
          -  Must have progressed within 6 months of adjuvant oxaliplatin-containing chemotherapy&#xD;
             and have no significant ongoing toxicity (excluding grade 1 neurotoxicity)&#xD;
&#xD;
          -  Measurable disease by RECIST criteria&#xD;
&#xD;
          -  No known brain or leptomeningeal metastases&#xD;
&#xD;
               -  Stable disease following surgical resection or radiosurgery of oligometastases&#xD;
                  allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (no prior transfusion) OR ≥ 10.0 g/dL (transfusion within past 4&#xD;
             weeks)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 times 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 times 10^9/L&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN with liver metastases)&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception during and for 3&#xD;
             months (female) or 2 months (male) after completion of study treatment&#xD;
&#xD;
          -  No active infection or serious concurrent medical condition&#xD;
&#xD;
          -  No significant cardiovascular disease including any of the following:&#xD;
&#xD;
               -  History of NYHA class II-IV congestive heart failure requiring therapy&#xD;
&#xD;
               -  History of unstable angina pectoris or myocardial infarction within the past 6&#xD;
                  months&#xD;
&#xD;
               -  Severe valvular heart disease&#xD;
&#xD;
               -  Ventricular arrhythmia requiring treatment&#xD;
&#xD;
               -  Prolonged QTc interval &gt; 470 msec&#xD;
&#xD;
          -  No concurrent medical condition, that in the investigator's judgement, will&#xD;
             substantially increase the risk associated with the patient's participation in the&#xD;
             study, or potentially hamper compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No psychiatric disorders or altered mental status precluding understanding of the&#xD;
             informed consent process and/or compliance with the study protocol&#xD;
&#xD;
          -  No gastrointestinal disorders likely to interfere with absorption of the study drug&#xD;
             (e.g., partial bowel obstruction or malabsorption)&#xD;
&#xD;
          -  No known serological positivity for hepatitis B or hepatitis C&#xD;
&#xD;
          -  No immunocompromised patients (e.g., no known serological positivity for HIV)&#xD;
&#xD;
          -  No other prior or current malignant disease likely to interfere with protocol&#xD;
             treatment or comparisons&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior zibotentan or irinotecan hydrochloride&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy, radiotherapy (except for palliative&#xD;
             reasons), endocrine therapy, or immunotherapy&#xD;
&#xD;
          -  No more than 1 prior course of chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior extensive radiotherapy (i.e., likely to deplete bone marrow reserve)&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided the dose is stable for 4 weeks and not&#xD;
             altered during the first 15 days of this study&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
               -  Low molecular weight heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Cancer Research and Cell Biology at Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wales Cancer Trials Unit</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF11 9LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiff University</investigator_affiliation>
    <investigator_full_name>Dr Anne Thomas</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

